[Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia]

Nihon Yakurigaku Zasshi. 2008 Dec;132(6):351-60. doi: 10.1254/fpj.132.351.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antidepressive Agents, Second-Generation* / adverse effects
  • Antidepressive Agents, Second-Generation* / pharmacology
  • Antidepressive Agents, Second-Generation* / therapeutic use
  • Cognition Disorders / drug therapy
  • Dopamine D2 Receptor Antagonists
  • Double-Blind Method
  • Drug Discovery
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Piperazines* / adverse effects
  • Piperazines* / pharmacology
  • Piperazines* / therapeutic use
  • Piperidines* / adverse effects
  • Piperidines* / pharmacology
  • Piperidines* / therapeutic use
  • Randomized Controlled Trials as Topic
  • Schizophrenia / drug therapy*
  • Serotonin 5-HT2 Receptor Antagonists
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Dopamine D2 Receptor Antagonists
  • Piperazines
  • Piperidines
  • Serotonin 5-HT2 Receptor Antagonists
  • blonanserin